Form 4: Coherus BioSciences CFO Reports Stock Transaction
SEC Form 4 Filing
Bryan J. McMichael, CFO of Coherus BioSciences, reports the withholding of shares to cover tax liabilities related to vesting restricted stock units.
Summary
- On January 7, 2025, Bryan J. McMichael, the Chief Financial Officer of Coherus BioSciences, Inc., had 1,711 shares of common stock withheld by the issuer to cover tax liabilities related to the vesting of restricted stock units.
- The price per share for the transaction was $1.57.
- Following the transaction, McMichael beneficially owns 24,662 shares of Coherus BioSciences common stock, which includes 3,401 shares acquired on May 15, 2023, through the Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by a company insider; it doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine tax-related stock withholding.
Key Dates
| Date | Description |
|---|---|
| 05/15/2023 | McMichael acquired 3,401 shares through the Employee Stock Purchase Plan. |
| 01/07/2025 | Transaction date: 1,711 shares withheld for tax liability. |
| 01/09/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.